Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new combo for tough lung cancer: Low-Dose radiation plus immunotherapy

NCT ID NCT07583550

Disease control Sponsor: Jiangmen Central Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to two years. The goal is to see if this approach helps control the cancer longer and improves survival. The study will enroll 43 adults who have not had prior treatment for their cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 43 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years and ≤75 years; 2. Histologically or cytologically confirmed SCLC; 3. No malignant pleural effusion or pericardial effusion; 4. No prior history of thoracic radiotherapy or thoracic surgery; 5. No prior systemic anti-tumor therapy; 6. ECOG performance status 0-2, with a life expectancy of ≥12 weeks; 7. At least one measurable lesion per RECIST 1.1 criteria; 8. No history of interstitial pneumonia; 9. No history of immune-related pneumonitis; 10. No history of autoimmune diseases; 11. No history of significant active pulmonary infection; 12. No use of corticosteroid therapy within 14 days prior to enrollment; 13. No Grade ≥3 hematologic toxicity or hepatic/renal impairment; 14. No brainstem metastases and no significant neurological symptoms; 15. For subjects with coexisting HBV/HCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy; 16. All subjects have provided written informed consent; Exclusion Criteria: 1. Presence of interstitial pneumonia or infectious fever prior to treatment; 2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment); 3. Prior history of thoracic radiotherapy or thoracic surgery; 4. Presence of Grade ≥3 hematologic toxicity or hepatic/renal impairment; 5. Hypersensitivity to adebrelimab; 6. Significant respiratory symptoms that preclude tolerance to radiotherapy; 7. Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above; 8. Presence of pleural effusion or pericardial effusion;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small-cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG Radiotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.